Avoid DOACs in patients with antiphospholid syndrome, TGA advises

Direct acting oral anticoagulants (DOACs) should not be used in patients with antiphospholipid syndrome (APS) due to a high risk of thrombotic events, the Therapeutic Goods Administration (TGA) has advised. In a new safety advisory statement the regulator says apixaban (Eliquis), dabigatran etexilate (Pradaxa) and rivaroxaban (Xarelto) are not recommended in patients with APS, particularly ...

Already a member?

Login to keep reading.

© 2021 the limbic